Physician profile
Omid Hakimian
NPI 1164418166
$2,967.02
in general payments reported to CMS, 2019-2025
14 companies · $1,618 in 2025
The $1,618 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $15.19 · 2022: $460 · 2023: $510 · 2024: $260 · 2025: $1,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625 · Travel and Lodging: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.60 |
| Travel and Lodging | $763.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calyxo, INC. | $1,290.03 | 2025 | Cvac Aspiration System |
| Abbott Laboratories | $275.00 | 2023-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $202.57 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $135.00 | 2023 | Austedo |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.94 | 2023 | Cycloset |
| C. R. Bard, INC. & Subsidiaries | $123.64 | 2022 | |
| Intuity Medical INC | $111.11 | 2022 | |
| Abbvie INC. | $110.39 | 2024 | |
| Janssen Pharmaceuticals, INC | $104.16 | 2019 | |
| Astellas Pharma US INC | $99.99 | 2022 | |
| Allergan, INC. | $15.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Hakimian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.